Suzanne A. W. Fuqua

Suzanne A. W. Fuqua

Auto-generated profile, based on publicly available information

Suzanne A. W. Fuqua

Lester & Sue Smith Breast Center, Baylor College of Medicine, Houston, USA

Research Focus & Metrics

Academic Career Length

33Years (1994-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
18 July 2019 in Cancer
Verified
Journal Article
Open access
PDF file
DDDerek Dustin
Derek Dustin
GGGuowei Gu
Guowei Gu
SFSuzanne A. W. Fuqua
Suzanne A. W. Fuqua
The acquisition of ligand‐independent ESR1 mutations during aromatase inhibitor therapy in metastatic estrogen receptor (ER)‐positive breast cancer is a common mechanism of hormonal therapy resistance. Preclinical and clinical studies have demonstrated that ESR1 mutations can preexist in primary tumors and can be enriched during metastasis. Furthermore, ESR1 mutations express a unique transcriptional profile that favors tumor progression, suggesting that selected ESR1 mutations may influence metastasis. Several groups have used sensitive detection methods using patient liquid biopsies to track ESR1 or truncal somatic mutations to predict treatment outcome and tumor progression, and some of these techniques may eventually be used to guide sequential treatment options in patients. Further development and standardization of mutation tracking in circulating tumor DNA is ongoing. Clinically, patients with ESR1 mutations derive clinical benefit when treated with fulvestrant and CDK4/6‐targeted therapies, but the development of more potent selective ER degraders and/or new targeted biotherapies are needed to overcome the endocrine‐resistant phenotype of ESR1 mutant–bearing tumors. In this review, we discuss the mechanisms of resistance and dissemination of ESR1 mutations as well as the detection methods for ESR1 mutation tracking, newly discovered potential therapeutic targets, and the clinical implications and treatment options for treating patients with ESR1 mutant–bearing tumors.

17 June 2009 in Breast Cancer Research and Treatment
Verified
Journal Article
Closed access
PDF file
FAFrancesca De Amicis
Francesca De Amicis
JTJanagi Thirugnansampanthan
Janagi Thirugnansampanthan
YCYukun Cui
Yukun Cui
JSJennifer Selever
Jennifer Selever
ABAmanda Beyer
Amanda Beyer
SFSuzanne A. W. Fuqua
Suzanne A. W. Fuqua

7 October 2021 in British Journal of Cancer
Verified
Journal Article
Closed access
PDF file
SHSarah K. Herzog
Sarah K. Herzog
SFSuzanne A. W. Fuqua
Suzanne A. W. Fuqua

13 May 2010 in Clinical Cancer Research
Verified
Journal Article
Closed access
PDF file
INES BARONEINES BARONE
INES BARONE
LBLauren Brusco
Lauren Brusco
SFSuzanne A.W. Fuqua
Suzanne A.W. Fuqua
Estrogens play a crucial role in regulating the growth and differentiation of breast cancers, with approximately two thirds of all breast tumors expressing the estrogen receptor alpha (ERα). Therefore, therapeutic strategies directed at inhibiting the action of ERα by using anti-estrogens such as tamoxifen, or reducing estrogens levels by using aromatase inhibitors, such as letrozole, anastrozole, or exemestane, are the standard treatments offered to women with ERα-positive cancer. However, not all patients respond to endocrine therapies (termed de novo resistance), and a large number of patients who do respond will eventually develop disease progression or recurrence while on therapy (acquired resistance). Recently, variant forms of the receptor have been identified owing to alternative splicing or gene mutation. This article reviews these variant receptors and their clinical relevance in resistance to endocrine therapy, by addressing their molecular cross-talk with growth factor receptors and signaling components. Understanding the complexity of receptor-mediated signaling has promise for new combined therapeutic options that focus on more efficient blockade of receptor cross-talk. Clin Cancer Res; 16(10); 2702–8. ©2010 AACR.

1 December 2016 in Current Opinion in Pharmacology
Verified
Journal Article
Closed access
GGGuowei Gu
Guowei Gu
DDDerek Dustin
Derek Dustin
SFSuzanne Aw Fuqua
Suzanne Aw Fuqua

2 September 2014 in Breast Cancer Research and Treatment
Verified
Journal Article
Closed access
PDF file
YRYassine Rechoum
Yassine Rechoum
DRDaniela Rovito
Daniela Rovito
Domenico IacopettaDomenico Iacopetta
Domenico Iacopetta
INES BARONEINES BARONE
INES BARONE
SASebastiano Andò
Sebastiano Andò
SFSuzanne A. W. Fuqua
Suzanne A. W. Fuqua